Remote Identification and the Road Map for the Future: Drones In America

 

Each week, Drones in America introduces listeners to guests who are leaders, influencers and experts with insight into America’s drone industry.

On this bonus episode, host Grant Guillot of the law firm Adams and Reese was joined by retired United States Air Force Colonel Dawn Zoldi, who currently is the Founder and CEO of P3 Tech Consulting, which looks to educate people passionate about drones and beyond in policies, programs and more.

Guillot and Zoldi took aim at remote identification, which Guillot labeled one of the most significant developments in recent years for the commercial drone industry.

According to the FAA, remote identification is “the ability of (an unmanned aircraft system) in flight to provide identification information that can be received by other parties.”

While the FAA outlines several perceived benefits of remote identification, including assisting law enforcement, federal agencies and more in identifying unsafe flight practices and vehicles and more robust enablement of safe, secure drone operations, concerns still exist surrounding privacy and more.

Guillot and Zoldi dove into all aspects of remote identification, providing listeners with expert-level insight into its current state, where it could go from here, and more.

Coming Soon!

Join us Thursday June 25th at 11am ET/10am CT for a webinar titled, “Young Leaders and Entrepreneurs in the Commercial Drone Industry” moderated by “Drones in America” host Grant Guillot. This program will feature a panel of Millennials and members of Generation Z, who will discuss successes and challenges they’ve faced in the commercial drone sector, the risks and rewards involved in pursuing a career in a nascent industry, and their hopes for influencing future generations of technological innovators.

Register here for the event.

 

Catch up on previous episodes of Drones In America!

Join host Grant Guillot of the law firm, Adams and Reese for Drones in America with new episodes available where ever podcasts are found.

Follow us on social media for the latest updates in B2B!

Image

Latest

ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More
vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More